Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 50
- Registration Number
- NCT03984097
- Locations
- 🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
Iontophoresis in Psoriasis
- Conditions
- Skin DiseasesPsoriasis VulgarisPsoriasis
- Interventions
- Device: Activapatch intellidose 2.5 using inactive IontophoresisDevice: Activapatch intellidose 2.5 using active IontophoresisDrug: Dexamethasone
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Wake Forest University Health Sciences
- Registration Number
- NCT03979664
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Comparison of Analgesic Efficacy Between of Interscalene Block With Liposomal Bupivacaine With Bupivacaine and Dexamethasone
- Conditions
- Total Shoulder ArthroplastyShoulder Osteoarthritis
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 90
- Registration Number
- NCT03969875
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Conditions
- Testicular LeukemiaB Lymphoblastic LymphomaB Acute Lymphoblastic LeukemiaMixed Phenotype Acute LeukemiaCentral Nervous System Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: Calaspargase PegolProcedure: Bone ScanDrug: CyclophosphamideProcedure: Computed TomographyDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: CytarabineDrug: Doxorubicin HydrochlorideDrug: Leucovorin CalciumBiological: Inotuzumab OzogamicinDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseProcedure: Magnetic Resonance ImagingDrug: PrednisoloneOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Positron Emission TomographyDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 4997
- Registration Number
- NCT03959085
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Michigan State University Clinical Center, East Lansing, Michigan, United States
🇺🇸Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
- Conditions
- Germ Cell Tumor
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Costantine Albany
- Registration Number
- NCT03960151
IPACK Study in Total Knee Arthroplasty Patients
- Conditions
- Knee Replacement Arthroplasty
- Interventions
- Drug: Standard of Care (ACB, SA, peri-op pain management)Drug: IPACK and multi-modal analgesic regimenProcedure: Periarticular Local Anesthetic InfiltrationDrug: IV Dexamethasone 8mg at the end of surgery as standard of care
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 78
- Registration Number
- NCT03954379
- Locations
- 🇨🇦
Toronto Western Hopspital, Toronto, Ontario, Canada
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- Drug: ElotuzumabDrug: CarfilzomibDrug: LenalidomideOther: autologous stem cell transplantDrug: Dexamethasone
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Wuerzburg University Hospital
- Target Recruit Count
- 576
- Registration Number
- NCT03948035
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Baden-Wuerttemberg, Germany
🇩🇪Vivantes Klinikum Spandau, Berlin, Germany
🇩🇪Universitätsklinikum Münster, Münster, North Rhine-Westphalia, Germany
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 49
- Registration Number
- NCT03942224
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- Biological: DaratumumabDrug: DexamethasoneOther: Quality-of-Life AssessmentDrug: LenalidomideOther: Questionnaire Administration
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 288
- Registration Number
- NCT03937635
- Locations
- 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Doctors Hospital, Columbus, Ohio, United States
🇺🇸West Penn Hospital, Pittsburgh, Pennsylvania, United States
Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM
- Conditions
- Tuberculosis MeningitisHIV-1-infection
- Interventions
- Drug: LinezolidDrug: Standard of Care anti-tuberculous therapyDrug: High dose rifampicinDrug: DexamethasoneDrug: Aspirin
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- University of Cape Town
- Target Recruit Count
- 52
- Registration Number
- NCT03927313
- Locations
- 🇿🇦
Mitchells Plain Hospital, Cape Town, Western Cape, South Africa
🇿🇦Livingstone Hospital, Port Elizabeth, Eastern Cape, South Africa
🇿🇦New Somerset Hospital, Cape Town, Western Cape, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.